219 related articles for article (PubMed ID: 12793088)
1. [Calcimimetic agents in the treatment of hyperparathyroidism secondary to chronic renal failure].
Negri AL; Slatopolsky EA
Medicina (B Aires); 2003; 63(2):165-71. PubMed ID: 12793088
[TBL] [Abstract][Full Text] [Related]
2. Future role of calcimimetics in end-stage renal disease.
Goodman WG; Turner SA
Adv Ren Replace Ther; 2002 Jul; 9(3):200-8. PubMed ID: 12203202
[TBL] [Abstract][Full Text] [Related]
3. Prevention of uremic bone disease using calcimimetic compounds.
Olgaard K; Lewin E
Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
[TBL] [Abstract][Full Text] [Related]
5. Calcimimetics and hyperparathyroidism.
Krebs LJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
[TBL] [Abstract][Full Text] [Related]
6. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
Nagano N; Nemeth EF
J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
[TBL] [Abstract][Full Text] [Related]
7. Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials.
Goodman WG
Pediatr Nephrol; 2003 Dec; 18(12):1206-10. PubMed ID: 14586685
[TBL] [Abstract][Full Text] [Related]
8. The calcium receptor and calcimimetics.
Wada M; Nagano N; Nemeth EF
Curr Opin Nephrol Hypertens; 1999 Jul; 8(4):429-33. PubMed ID: 10491737
[TBL] [Abstract][Full Text] [Related]
9. Calcimimetic agents: review and perspectives.
Ureña P; Frazão JM
Kidney Int Suppl; 2003 Jun; (85):S91-6. PubMed ID: 12753275
[TBL] [Abstract][Full Text] [Related]
10. Calcimimetic agents and the calcium-sensing receptor.
Coburn JW; Maung HM
Curr Opin Nephrol Hypertens; 2000 Mar; 9(2):123-32. PubMed ID: 10757216
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
Nagano N
Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
[TBL] [Abstract][Full Text] [Related]
12. Recent updates on the calcium-sensing receptor as a drug target.
Trivedi R; Mithal A; Chattopadhyay N
Curr Med Chem; 2008; 15(2):178-86. PubMed ID: 18220773
[TBL] [Abstract][Full Text] [Related]
13. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration.
Díaz-Tocados JM; Rodríguez-Ortiz ME; Almadén Y; Pineda C; Martínez-Moreno JM; Herencia C; Vergara N; Pendón-Ruiz de Mier MV; Santamaría R; Rodelo-Haad C; Casado-Díaz A; Lorenzo V; Carvalho C; Frazão JM; Felsenfeld AJ; Richards WG; Aguilera-Tejero E; Rodríguez M; López I; Muñoz-Castañeda JR
Kidney Int; 2019 May; 95(5):1064-1078. PubMed ID: 30878213
[TBL] [Abstract][Full Text] [Related]
14. Calcimimetic agents for the treatment of secondary hyperparathyroidism.
Goodman WG
Semin Nephrol; 2004 Sep; 24(5):460-3. PubMed ID: 15490411
[TBL] [Abstract][Full Text] [Related]
15. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
Lindberg JS
Kidney Int Suppl; 2005 Jun; (95):S33-6. PubMed ID: 15882311
[TBL] [Abstract][Full Text] [Related]
16. Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis.
Drüeke TB
Nephrol Dial Transplant; 2002; 17 Suppl 11():20-2. PubMed ID: 12386252
[TBL] [Abstract][Full Text] [Related]
17. The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.
Rodríguez M; Goodman WG; Liakopoulos V; Messa P; Wiecek A; Cunningham J
Semin Dial; 2015; 28(5):497-507. PubMed ID: 25752650
[TBL] [Abstract][Full Text] [Related]
18. Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro.
Almaden Y; Rodriguez-Ortiz ME; Canalejo A; Cañadillas S; Canalejo R; Martin D; Aguilera-Tejero E; Rodríguez M
J Nephrol; 2009; 22(2):281-8. PubMed ID: 19384847
[TBL] [Abstract][Full Text] [Related]
19. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
Mizobuchi M; Hatamura I; Ogata H; Saji F; Uda S; Shiizaki K; Sakaguchi T; Negi S; Kinugasa E; Koshikawa S; Akizawa T
J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262
[TBL] [Abstract][Full Text] [Related]
20. [Calcimimetics, mechanisms of action and therapeutic applications].
Ureña P; Legoupil N; de Vernejoul MC
Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
